BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...SwanBio Therapeutics Ltd. hired Steven Zelenkofske as CMO, a new position. He was CMO of Achillion Pharmaceuticals Inc....
BioCentury | May 9, 2020
Management Tracks

O’Connor joins TG Therapeutics as CSO; plus changes at FogPharma, Gemini, Dicerna, Akcea and more

...Gibney as CFO and CBO, both newly created positions. He was EVP and CBO of Achillion Pharmaceuticals Inc....
...will succeed Sandra Rojas-Caro as CMO. Uknis was VP and global nephrology development lead at Achillion...
BioCentury | May 6, 2020
Management Tracks

Abrams resigns as Editas CMO; plus Immunocore, Spruce, Frazier, Horama and more

...Paul Fry, who stepped down as CFO in 2018. Donato was SVP and CFO of Achillion Pharmaceuticals Inc....
BioCentury | May 5, 2020
Deals

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

...the past few years has generally led to deals for clinical-stage companies. Its takeouts of Achillion Pharmaceuticals Inc....
...to diversify the company’s offerings beyond Soliris and Ultomiris following management changes in 2017 (see “Achillion’s...
BioCentury | Apr 14, 2020
Management Tracks

Kelly joins CytoDyn as CMO amid COVID-19 trials; plus Antengene, Genetron, Bolt, BioSpecifics, CMAB and more

...has stepped down and Joseph Truitt will serve as interim CEO. Truitt was CEO of Achillion Pharmaceuticals Inc....
BioCentury | Jan 8, 2020
Clinical News

Apellis readies to compete with Soliris in PNH based on Phase III data

...the most advanced complement inhibitor for PNH in the clinic. Danicopan, a CFD inhibitor from Achillion Pharmaceuticals Inc....
...to buy Achillion for $930 million in cash (see “Deal Streak Continues for Alexion as Achillion’s...
BioCentury | Dec 20, 2019
Clinical News

Stealth cites endpoints in Phase III mitochondrial disease miss

...building up its pipeline since a 2017 restructuring (see “Deal Streak Continues for Alexion as Achillion’s...
BioCentury | Oct 19, 2019
Finance

Achillion’s journey to $1 billion

...of an HCV deal with Johnson & Johnson (NYSE:JNJ). Figure: Achillion Chronicles Selected events for Achillion Pharmaceuticals Inc....
...The deal has a 73% premium to Achillion’s close of $3.65 on Tuesday and values Achillion...
...drugs in PNH, and Achillion is one of its only mid- to late-stage competitors. Becoming Achillion...
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from...
...The deal has a 73% premium to Achillion’s close of $3.65 on Tuesday and values Achillion...
...drugs in PNH, and Achillion is one of its only mid- to late-stage competitors. Becoming Achillion...
BioCentury | Jul 31, 2019
Company News

Apelian to lead new T cell company BlueSphere

...at Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) in May. Before his tenure there, he was CMO of Achillion Pharmaceuticals Inc....
Items per page:
1 - 10 of 335
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...SwanBio Therapeutics Ltd. hired Steven Zelenkofske as CMO, a new position. He was CMO of Achillion Pharmaceuticals Inc....
BioCentury | May 9, 2020
Management Tracks

O’Connor joins TG Therapeutics as CSO; plus changes at FogPharma, Gemini, Dicerna, Akcea and more

...Gibney as CFO and CBO, both newly created positions. He was EVP and CBO of Achillion Pharmaceuticals Inc....
...will succeed Sandra Rojas-Caro as CMO. Uknis was VP and global nephrology development lead at Achillion...
BioCentury | May 6, 2020
Management Tracks

Abrams resigns as Editas CMO; plus Immunocore, Spruce, Frazier, Horama and more

...Paul Fry, who stepped down as CFO in 2018. Donato was SVP and CFO of Achillion Pharmaceuticals Inc....
BioCentury | May 5, 2020
Deals

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

...the past few years has generally led to deals for clinical-stage companies. Its takeouts of Achillion Pharmaceuticals Inc....
...to diversify the company’s offerings beyond Soliris and Ultomiris following management changes in 2017 (see “Achillion’s...
BioCentury | Apr 14, 2020
Management Tracks

Kelly joins CytoDyn as CMO amid COVID-19 trials; plus Antengene, Genetron, Bolt, BioSpecifics, CMAB and more

...has stepped down and Joseph Truitt will serve as interim CEO. Truitt was CEO of Achillion Pharmaceuticals Inc....
BioCentury | Jan 8, 2020
Clinical News

Apellis readies to compete with Soliris in PNH based on Phase III data

...the most advanced complement inhibitor for PNH in the clinic. Danicopan, a CFD inhibitor from Achillion Pharmaceuticals Inc....
...to buy Achillion for $930 million in cash (see “Deal Streak Continues for Alexion as Achillion’s...
BioCentury | Dec 20, 2019
Clinical News

Stealth cites endpoints in Phase III mitochondrial disease miss

...building up its pipeline since a 2017 restructuring (see “Deal Streak Continues for Alexion as Achillion’s...
BioCentury | Oct 19, 2019
Finance

Achillion’s journey to $1 billion

...of an HCV deal with Johnson & Johnson (NYSE:JNJ). Figure: Achillion Chronicles Selected events for Achillion Pharmaceuticals Inc....
...The deal has a 73% premium to Achillion’s close of $3.65 on Tuesday and values Achillion...
...drugs in PNH, and Achillion is one of its only mid- to late-stage competitors. Becoming Achillion...
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from...
...The deal has a 73% premium to Achillion’s close of $3.65 on Tuesday and values Achillion...
...drugs in PNH, and Achillion is one of its only mid- to late-stage competitors. Becoming Achillion...
BioCentury | Jul 31, 2019
Company News

Apelian to lead new T cell company BlueSphere

...at Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) in May. Before his tenure there, he was CMO of Achillion Pharmaceuticals Inc....
Items per page:
1 - 10 of 335